NO311644B1 - Vitronektinreseptor-antagonister, farmasöytisk preparat inneholdende disse og anvendelse derav - Google Patents
Vitronektinreseptor-antagonister, farmasöytisk preparat inneholdende disse og anvendelse derav Download PDFInfo
- Publication number
- NO311644B1 NO311644B1 NO19975976A NO975976A NO311644B1 NO 311644 B1 NO311644 B1 NO 311644B1 NO 19975976 A NO19975976 A NO 19975976A NO 975976 A NO975976 A NO 975976A NO 311644 B1 NO311644 B1 NO 311644B1
- Authority
- NO
- Norway
- Prior art keywords
- arom
- mmol
- methylene chloride
- silica gel
- oxo
- Prior art date
Links
- 102100022337 Integrin alpha-V Human genes 0.000 title claims description 33
- 108010048673 Vitronectin Receptors Proteins 0.000 title claims description 27
- 239000002464 receptor antagonist Substances 0.000 title claims description 8
- 229940044551 receptor antagonist Drugs 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 61
- 150000001875 compounds Chemical class 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 16
- 210000002997 osteoclast Anatomy 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000008619 cell matrix interaction Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 230000008611 intercellular interaction Effects 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 258
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 195
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 99
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 81
- 239000000741 silica gel Substances 0.000 description 81
- 229910002027 silica gel Inorganic materials 0.000 description 81
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 73
- 239000000243 solution Substances 0.000 description 48
- 238000005160 1H NMR spectroscopy Methods 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 230000002829 reductive effect Effects 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 25
- 235000019439 ethyl acetate Nutrition 0.000 description 24
- 238000010828 elution Methods 0.000 description 23
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 23
- 238000001819 mass spectrum Methods 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 238000000160 carbon, hydrogen and nitrogen elemental analysis Methods 0.000 description 18
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 16
- 239000002244 precipitate Substances 0.000 description 16
- 150000001408 amides Chemical class 0.000 description 15
- 239000012298 atmosphere Substances 0.000 description 15
- 238000004587 chromatography analysis Methods 0.000 description 15
- -1 e.g. Na Chemical class 0.000 description 15
- 239000011261 inert gas Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000008018 melting Effects 0.000 description 13
- 238000002844 melting Methods 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 101000803709 Homo sapiens Vitronectin Proteins 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 238000010998 test method Methods 0.000 description 10
- 208000006386 Bone Resorption Diseases 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 230000024279 bone resorption Effects 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 8
- 239000002319 fibrinogen receptor antagonist Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 210000002805 bone matrix Anatomy 0.000 description 7
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 108010059557 kistrin Proteins 0.000 description 5
- ZTYNVDHJNRIRLL-FWZKYCSMSA-N rhodostomin Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CSSC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(O)=O)[C@@H](C)O)=O)CSSC[C@H]2C(=O)N[C@H]3CSSC[C@@H](C(NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]2NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)CN)CSSC2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N4)=O)CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CCCCN)C(=O)N1)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=CC=C1 ZTYNVDHJNRIRLL-FWZKYCSMSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 4
- 108010012088 Fibrinogen Receptors Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- GUTOOFAUODQZRP-UHFFFAOYSA-N tert-butyl 3-amino-2-(phenylmethoxycarbonylamino)propanoate Chemical compound CC(C)(C)OC(=O)C(CN)NC(=O)OCC1=CC=CC=C1 GUTOOFAUODQZRP-UHFFFAOYSA-N 0.000 description 4
- JAELLLITIZHOGQ-UHFFFAOYSA-N tert-butyl propanoate Chemical compound CCC(=O)OC(C)(C)C JAELLLITIZHOGQ-UHFFFAOYSA-N 0.000 description 4
- GXMCJXMABRKXAI-UHFFFAOYSA-N 5-(4-ethoxy-4-oxobutyl)-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazine-2-carboxylic acid Chemical compound O=C1N(CCCC(=O)OCC)CCN2N=C(C(O)=O)C=C21 GXMCJXMABRKXAI-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- GUTOOFAUODQZRP-LBPRGKRZSA-N tert-butyl (2s)-3-amino-2-(phenylmethoxycarbonylamino)propanoate Chemical compound CC(C)(C)OC(=O)[C@H](CN)NC(=O)OCC1=CC=CC=C1 GUTOOFAUODQZRP-LBPRGKRZSA-N 0.000 description 3
- PCGCVGFKQXDPQU-HNNXBMFYSA-N (2s)-3-[[5-[3-(diaminomethylideneamino)-3-oxopropyl]-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazine-2-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound N([C@@H](CNC(=O)C1=NN2CCN(C(C2=C1)=O)CCC(=O)NC(=N)N)C(O)=O)C(=O)OCC1=CC=CC=C1 PCGCVGFKQXDPQU-HNNXBMFYSA-N 0.000 description 2
- XNCYRYDEHOIVLD-INIZCTEOSA-N (2s)-3-[[5-[4-(diaminomethylideneamino)-4-oxobutyl]-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazine-2-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound N([C@@H](CNC(=O)C1=NN2CCN(C(C2=C1)=O)CCCC(=O)NC(=N)N)C(O)=O)C(=O)OCC1=CC=CC=C1 XNCYRYDEHOIVLD-INIZCTEOSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- XLBBKEHLEPNMMF-SSUNCQRMSA-N 129038-42-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)[C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O)C1=CC=CC=C1 XLBBKEHLEPNMMF-SSUNCQRMSA-N 0.000 description 2
- XZIRFQHNROXBQH-UHFFFAOYSA-N 2-(2-ethoxy-2-oxoethyl)-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid Chemical compound C1=CC(C(O)=O)=CN2C(=O)N(CC(=O)OCC)N=C21 XZIRFQHNROXBQH-UHFFFAOYSA-N 0.000 description 2
- JRSYAJRNZLOUDR-UHFFFAOYSA-N 2-(3-ethoxy-3-oxopropyl)-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid Chemical compound C1=CC(C(O)=O)=CN2C(=O)N(CCC(=O)OCC)N=C21 JRSYAJRNZLOUDR-UHFFFAOYSA-N 0.000 description 2
- CNPGPZPOEPXWHK-UHFFFAOYSA-N 2-(3-methoxy-3-oxopropyl)-3h-benzimidazole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2NC(CCC(=O)OC)=NC2=C1 CNPGPZPOEPXWHK-UHFFFAOYSA-N 0.000 description 2
- ZSUUXBZXCRHSGV-UHFFFAOYSA-N 2-(4-ethoxy-4-oxobutyl)-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid Chemical compound C1=CC(C(O)=O)=CN2C(=O)N(CCCC(=O)OCC)N=C21 ZSUUXBZXCRHSGV-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- YPUUGZHPAKHJKS-UHFFFAOYSA-N 3-[6-[2-(diaminomethylideneamino)-2-oxoethoxy]-1-oxo-3,4-dihydroisoquinolin-2-yl]-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C1CC2=CC(OCC(=O)NC(=N)N)=CC=C2C(=O)N1CC(C(O)=O)NC(=O)OCC1=CC=CC=C1 YPUUGZHPAKHJKS-UHFFFAOYSA-N 0.000 description 2
- CROCADFUAQHRCX-UHFFFAOYSA-N 3-[[2-[3-(diaminomethylideneamino)-3-oxopropyl]-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C=1N2C(=O)N(CCC(=O)NC(=N)N)N=C2C=CC=1C(=O)NCC(C(O)=O)NC(=O)OCC1=CC=CC=C1 CROCADFUAQHRCX-UHFFFAOYSA-N 0.000 description 2
- NWDNWGSTTAAJHD-UHFFFAOYSA-N 3-[[2-[4-(diaminomethylideneamino)-4-oxobutyl]-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C=1N2C(=O)N(CCCC(=O)NC(=N)N)N=C2C=CC=1C(=O)NCC(C(O)=O)NC(=O)OCC1=CC=CC=C1 NWDNWGSTTAAJHD-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MJSHDCCLFGOEIK-UHFFFAOYSA-N benzyl (2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)OCC1=CC=CC=C1 MJSHDCCLFGOEIK-UHFFFAOYSA-N 0.000 description 2
- LOSPCUILGMWLCQ-UHFFFAOYSA-N benzyl 5-(3-ethoxy-3-oxopropyl)-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazine-2-carboxylate Chemical compound C1=C2C(=O)N(CCC(=O)OCC)CCN2N=C1C(=O)OCC1=CC=CC=C1 LOSPCUILGMWLCQ-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- JLHWYDAIYYMBBZ-UHFFFAOYSA-N dibenzyl 1-(2-bromoethyl)pyrazole-3,5-dicarboxylate Chemical compound BrCCN1N=C(C(=O)OCC=2C=CC=CC=2)C=C1C(=O)OCC1=CC=CC=C1 JLHWYDAIYYMBBZ-UHFFFAOYSA-N 0.000 description 2
- DCWHWMRASOBMRY-UHFFFAOYSA-N dibenzyl 1h-pyrazole-3,5-dicarboxylate Chemical compound C1=C(C(=O)OCC=2C=CC=CC=2)NN=C1C(=O)OCC1=CC=CC=C1 DCWHWMRASOBMRY-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 108010025752 echistatin Proteins 0.000 description 2
- YYMFGIFNQGIWMV-NRFANRHFSA-N ethyl 4-[2-[[(2s)-3-[(2-methylpropan-2-yl)oxy]-3-oxo-2-(phenylmethoxycarbonylamino)propyl]carbamoyl]-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazin-5-yl]butanoate Chemical compound N([C@@H](CNC(=O)C1=NN2CCN(C(C2=C1)=O)CCCC(=O)OCC)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 YYMFGIFNQGIWMV-NRFANRHFSA-N 0.000 description 2
- XBTIQVVPRQDCMT-UHFFFAOYSA-N ethyl 4-[6-[[3-[(2-methylpropan-2-yl)oxy]-3-oxo-2-(phenylmethoxycarbonylamino)propyl]carbamoyl]-3-oxo-[1,2,4]triazolo[4,3-a]pyridin-2-yl]butanoate Chemical compound C=1N2C(=O)N(CCCC(=O)OCC)N=C2C=CC=1C(=O)NCC(C(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 XBTIQVVPRQDCMT-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- MVOCSMTVNYFNFI-UHFFFAOYSA-N methyl 2-acetamido-3-(1-oxo-6-phenylmethoxy-3,4-dihydroisoquinolin-2-yl)propanoate Chemical compound C=1C=C2C(=O)N(CC(C(=O)OC)NC(C)=O)CCC2=CC=1OCC1=CC=CC=C1 MVOCSMTVNYFNFI-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- KUNSXBZEVBDRRV-FQEVSTJZSA-N tert-butyl (2s)-3-[[5-(3-ethoxy-3-oxopropyl)-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazine-2-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound N([C@@H](CNC(=O)C1=NN2CCN(C(C2=C1)=O)CCC(=O)OCC)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 KUNSXBZEVBDRRV-FQEVSTJZSA-N 0.000 description 2
- FPRRQQFKGALAFT-UHFFFAOYSA-N tert-butyl 2-(2-ethoxy-2-oxoethyl)-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CN2C(=O)N(CC(=O)OCC)N=C21 FPRRQQFKGALAFT-UHFFFAOYSA-N 0.000 description 2
- SDJHWMGKOMJHEJ-UHFFFAOYSA-N tert-butyl 2-(3-ethoxy-3-oxopropyl)-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CN2C(=O)N(CCC(=O)OCC)N=C21 SDJHWMGKOMJHEJ-UHFFFAOYSA-N 0.000 description 2
- CBDBNLPOZLBFHD-UHFFFAOYSA-N tert-butyl 2-(4-ethoxy-4-oxobutyl)-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CN2C(=O)N(CCCC(=O)OCC)N=C21 CBDBNLPOZLBFHD-UHFFFAOYSA-N 0.000 description 2
- KWDPRKQYURTFCZ-UHFFFAOYSA-N tert-butyl 2-amino-3-(6-hydroxy-1-oxo-3,4-dihydroisoquinolin-2-yl)propanoate Chemical compound OC1=CC=C2C(=O)N(CC(N)C(=O)OC(C)(C)C)CCC2=C1 KWDPRKQYURTFCZ-UHFFFAOYSA-N 0.000 description 2
- ZEXNHDUIGLPXLX-UHFFFAOYSA-N tert-butyl 3-(1-oxo-6-phenylmethoxy-3,4-dihydroisoquinolin-2-yl)-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C=1C=CC=CC=1COC(=O)NC(C(=O)OC(C)(C)C)CN(C(C1=CC=2)=O)CCC1=CC=2OCC1=CC=CC=C1 ZEXNHDUIGLPXLX-UHFFFAOYSA-N 0.000 description 2
- UZLFLQJTCWHUHA-UHFFFAOYSA-N tert-butyl 3-[6-(2-methoxy-2-oxoethoxy)-1-oxo-3,4-dihydroisoquinolin-2-yl]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C1CC2=CC(OCC(=O)OC)=CC=C2C(=O)N1CC(C(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 UZLFLQJTCWHUHA-UHFFFAOYSA-N 0.000 description 2
- ZRORNNOBFZSWDU-UHFFFAOYSA-N tert-butyl 3-[6-[2-(diaminomethylideneamino)-2-oxoethoxy]-1-oxo-3,4-dihydroisoquinolin-2-yl]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C1CC2=CC(OCC(=O)N=C(N)N)=CC=C2C(=O)N1CC(C(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 ZRORNNOBFZSWDU-UHFFFAOYSA-N 0.000 description 2
- ZAZSYXMWSNVPDI-UHFFFAOYSA-N tert-butyl 3-[[2-(3-ethoxy-3-oxopropyl)-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C=1N2C(=O)N(CCC(=O)OCC)N=C2C=CC=1C(=O)NCC(C(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 ZAZSYXMWSNVPDI-UHFFFAOYSA-N 0.000 description 2
- NQXKCEAXNMCCAO-UHFFFAOYSA-N tert-butyl 3-[[2-(3-methoxy-3-oxopropyl)-3h-benzimidazole-5-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C1=C2NC(CCC(=O)OC)=NC2=CC=C1C(=O)NCC(C(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 NQXKCEAXNMCCAO-UHFFFAOYSA-N 0.000 description 2
- KIIMCLKSQNBKFR-UHFFFAOYSA-N tert-butyl 3-[[2-[3-(diaminomethylideneamino)-3-oxopropyl]-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C1=CC2=NN(CCC(=O)N=C(N)N)C(=O)N2C=C1C(=O)NCC(C(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 KIIMCLKSQNBKFR-UHFFFAOYSA-N 0.000 description 2
- DEVHDDHJHDTBIR-UHFFFAOYSA-N tert-butyl 3-oxo-2h-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylate Chemical compound C1=C(C(=O)OC(C)(C)C)C=CC2=NNC(=O)N21 DEVHDDHJHDTBIR-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- FOXRXVSTFGNURG-VIFPVBQESA-N (2s)-3-amino-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound NC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 FOXRXVSTFGNURG-VIFPVBQESA-N 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- YDMVPJZBYSWOOP-UHFFFAOYSA-N 1h-pyrazole-3,5-dicarboxylic acid Chemical compound OC(=O)C=1C=C(C(O)=O)NN=1 YDMVPJZBYSWOOP-UHFFFAOYSA-N 0.000 description 1
- HEMGYNNCNNODNX-UHFFFAOYSA-N 3,4-diaminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1N HEMGYNNCNNODNX-UHFFFAOYSA-N 0.000 description 1
- PLJYJFLAHREIDB-UHFFFAOYSA-N 3-(1-oxo-6-phenylmethoxy-3,4-dihydroisoquinolin-2-yl)-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C=1C=CC=CC=1COC(=O)NC(C(=O)O)CN(C(C1=CC=2)=O)CCC1=CC=2OCC1=CC=CC=C1 PLJYJFLAHREIDB-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- LMMYEXRIQUEHQV-UHFFFAOYSA-N 3-[[2-[2-(diaminomethylideneamino)-2-oxoethyl]-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C=1N2C(=O)N(CC(=O)NC(=N)N)N=C2C=CC=1C(=O)NCC(C(O)=O)NC(=O)OCC1=CC=CC=C1 LMMYEXRIQUEHQV-UHFFFAOYSA-N 0.000 description 1
- ADZYHTYHFOXCEY-UHFFFAOYSA-N 5-(3-ethoxy-3-oxopropyl)-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazine-2-carboxylic acid Chemical compound O=C1N(CCC(=O)OCC)CCN2N=C(C(O)=O)C=C21 ADZYHTYHFOXCEY-UHFFFAOYSA-N 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 208000018035 Dental disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 229940127449 Integrin Receptor Antagonists Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- XKDJJORFULXQGX-UHFFFAOYSA-N benzyl 5-(4-ethoxy-4-oxobutyl)-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazine-2-carboxylate Chemical compound C1=C2C(=O)N(CCCC(=O)OCC)CCN2N=C1C(=O)OCC1=CC=CC=C1 XKDJJORFULXQGX-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037176 bone building Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RJCGNNHKSNIUAT-UHFFFAOYSA-N ethyl 3-aminopropanoate;hydron;chloride Chemical compound Cl.CCOC(=O)CCN RJCGNNHKSNIUAT-UHFFFAOYSA-N 0.000 description 1
- FQTIYMRSUOADDK-UHFFFAOYSA-N ethyl 3-bromopropanoate Chemical compound CCOC(=O)CCBr FQTIYMRSUOADDK-UHFFFAOYSA-N 0.000 description 1
- CXVQSUBJMYZELD-UHFFFAOYSA-N ethyl 4-aminobutanoate;hydrochloride Chemical compound [Cl-].CCOC(=O)CCC[NH3+] CXVQSUBJMYZELD-UHFFFAOYSA-N 0.000 description 1
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- SMWNFFKPVLVOQQ-UHFFFAOYSA-N methyl 2-acetamidoprop-2-enoate Chemical compound COC(=O)C(=C)NC(C)=O SMWNFFKPVLVOQQ-UHFFFAOYSA-N 0.000 description 1
- MCHBTJDVKZSVGL-UHFFFAOYSA-N methyl 2-amino-3-(1-oxo-6-phenylmethoxy-3,4-dihydroisoquinolin-2-yl)propanoate Chemical compound C=1C=C2C(=O)N(CC(N)C(=O)OC)CCC2=CC=1OCC1=CC=CC=C1 MCHBTJDVKZSVGL-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- ATJAKRSSOQTHHP-UHFFFAOYSA-N methyl 3-(1-oxo-6-phenylmethoxy-3,4-dihydroisoquinolin-2-yl)-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C=1C=CC=CC=1COC(=O)NC(C(=O)OC)CN(C(C1=CC=2)=O)CCC1=CC=2OCC1=CC=CC=C1 ATJAKRSSOQTHHP-UHFFFAOYSA-N 0.000 description 1
- SRXOJMOGPYFZKC-UHFFFAOYSA-N methyl 4-chloro-4-oxobutanoate Chemical compound COC(=O)CCC(Cl)=O SRXOJMOGPYFZKC-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- DBNQIOANXZVWIP-UHFFFAOYSA-N n,n-dimethyl-1,1-bis[(2-methylpropan-2-yl)oxy]methanamine Chemical compound CC(C)(C)OC(N(C)C)OC(C)(C)C DBNQIOANXZVWIP-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- NPBMKMCDZDOZTN-SFHVURJKSA-N tert-butyl (2s)-3-[[5-[3-(diaminomethylideneamino)-3-oxopropyl]-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazine-2-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound N([C@@H](CNC(=O)C1=NN2CCN(CCC(=O)NC(N)=N)C(=O)C2=C1)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 NPBMKMCDZDOZTN-SFHVURJKSA-N 0.000 description 1
- FUYKHKRTRATNRT-IBGZPJMESA-N tert-butyl (2s)-3-[[5-[4-(diaminomethylideneamino)-4-oxobutyl]-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazine-2-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound N([C@@H](CNC(=O)C1=NN2CCN(CCCC(=O)NC(N)=N)C(=O)C2=C1)C(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 FUYKHKRTRATNRT-IBGZPJMESA-N 0.000 description 1
- JAAILYCQBSJBGX-UHFFFAOYSA-N tert-butyl 2-(3-methoxy-3-oxopropyl)-5-[[3-[(2-methylpropan-2-yl)oxy]-3-oxo-2-(phenylmethoxycarbonylamino)propyl]carbamoyl]benzimidazole-1-carboxylate Chemical compound C=1C=C2N(C(=O)OC(C)(C)C)C(CCC(=O)OC)=NC2=CC=1C(=O)NCC(C(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 JAAILYCQBSJBGX-UHFFFAOYSA-N 0.000 description 1
- VAVDXQOJPOSZJS-UHFFFAOYSA-N tert-butyl 2-(3-methoxy-3-oxopropyl)-6-[[3-[(2-methylpropan-2-yl)oxy]-3-oxo-2-(phenylmethoxycarbonylamino)propyl]carbamoyl]benzimidazole-1-carboxylate Chemical compound C1=C2N(C(=O)OC(C)(C)C)C(CCC(=O)OC)=NC2=CC=C1C(=O)NCC(C(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 VAVDXQOJPOSZJS-UHFFFAOYSA-N 0.000 description 1
- GUQXEHPUAKWKQM-UHFFFAOYSA-N tert-butyl 3-(6-hydroxy-1-oxo-3,4-dihydroisoquinolin-2-yl)-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C1CC2=CC(O)=CC=C2C(=O)N1CC(C(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 GUQXEHPUAKWKQM-UHFFFAOYSA-N 0.000 description 1
- GWGFNSBRLJNSBT-UHFFFAOYSA-N tert-butyl 3-[[2-(2-ethoxy-2-oxoethyl)-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C=1N2C(=O)N(CC(=O)OCC)N=C2C=CC=1C(=O)NCC(C(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 GWGFNSBRLJNSBT-UHFFFAOYSA-N 0.000 description 1
- YZWVWCPQYUHAAI-UHFFFAOYSA-N tert-butyl 3-[[2-[2-(diaminomethylideneamino)-2-oxoethyl]-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C1=CC2=NN(CC(=O)N=C(N)N)C(=O)N2C=C1C(=O)NCC(C(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 YZWVWCPQYUHAAI-UHFFFAOYSA-N 0.000 description 1
- BGNPJHAXIPPJEI-UHFFFAOYSA-N tert-butyl 3-[[2-[4-(diaminomethylideneamino)-4-oxobutyl]-3-oxo-[1,2,4]triazolo[4,3-a]pyridine-6-carbonyl]amino]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C1=CC2=NN(CCCC(=O)N=C(N)N)C(=O)N2C=C1C(=O)NCC(C(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 BGNPJHAXIPPJEI-UHFFFAOYSA-N 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- LFQCEHFDDXELDD-UHFFFAOYSA-N tetramethyl orthosilicate Chemical compound CO[Si](OC)(OC)OC LFQCEHFDDXELDD-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000012749 thinning agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19653647A DE19653647A1 (de) | 1996-12-20 | 1996-12-20 | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO975976D0 NO975976D0 (no) | 1997-12-19 |
| NO975976L NO975976L (no) | 1998-06-22 |
| NO311644B1 true NO311644B1 (no) | 2001-12-27 |
Family
ID=7815762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19975976A NO311644B1 (no) | 1996-12-20 | 1997-12-19 | Vitronektinreseptor-antagonister, farmasöytisk preparat inneholdende disse og anvendelse derav |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US6011045A (ja) |
| EP (1) | EP0854140B1 (ja) |
| JP (1) | JP4081167B2 (ja) |
| KR (1) | KR19980064656A (ja) |
| CN (2) | CN1103775C (ja) |
| AR (1) | AR010370A1 (ja) |
| AU (1) | AU730737B2 (ja) |
| BR (1) | BR9706385A (ja) |
| CA (1) | CA2225273A1 (ja) |
| CZ (1) | CZ411397A3 (ja) |
| DE (1) | DE19653647A1 (ja) |
| HU (1) | HUP9702508A3 (ja) |
| ID (1) | ID19253A (ja) |
| IL (1) | IL122641A0 (ja) |
| MX (1) | MX9710392A (ja) |
| NO (1) | NO311644B1 (ja) |
| NZ (1) | NZ329430A (ja) |
| PL (1) | PL323970A1 (ja) |
| RU (1) | RU2198892C2 (ja) |
| TW (1) | TW523510B (ja) |
| ZA (1) | ZA9711316B (ja) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20012320A3 (cs) | 1998-12-23 | 2002-10-16 | G. D. Searle & Co. | Léčivo s obsahem inhibitoru cyklooxygenázy-2 a jednoho nebo více antineoplastických činidel pro kombinační terapii při léčení neoplasie |
| US6395897B1 (en) | 1999-03-02 | 2002-05-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5 |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| US6545032B1 (en) * | 1999-09-17 | 2003-04-08 | Torrey Pines Institute For Molecular Studies | Synthesis of [3,5,7]-H-imidazo[1,5-a] imidazol-2(3H)-one compounds |
| CO5261573A1 (es) | 1999-11-19 | 2003-03-31 | Novartis Ag | Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion |
| US20040136949A1 (en) | 2001-04-24 | 2004-07-15 | Matthias Grell | Combination therapy using anti-angiogenic agents and tnf alpha |
| EP2428226A1 (en) | 2001-10-22 | 2012-03-14 | The Scripps Research Institute | Antibody targeting compounds |
| US8440217B1 (en) | 2005-06-15 | 2013-05-14 | Mawaheb M. EL-Naggar | Method and system with contact lens product for treating and preventing adverse eye conditions |
| JP2009512443A (ja) * | 2005-10-20 | 2009-03-26 | ザ スクリップス リサーチ インスチチュート | 免疫染色及び免疫標的化のためのＦｃ標識化 |
| AR056155A1 (es) * | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
| US7615075B2 (en) * | 2005-11-04 | 2009-11-10 | Rush University Medical Center | Plastic implant impregnated with a degradation protector |
| EP2338518A1 (en) | 2006-01-18 | 2011-06-29 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
| US7553836B2 (en) * | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
| MX2009007597A (es) | 2007-01-18 | 2009-07-22 | Merck Patent Gmbh | Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer. |
| DE102007012210B4 (de) * | 2007-03-08 | 2009-10-15 | Filt Lungen- Und Thoraxdiagnostik Gmbh | Transportabler Pneumotachograph zur Messung von Bestandteilen des Exspirationsvolumens sowie ein Verfahren hierzu |
| DK2124562T3 (en) | 2007-03-09 | 2016-08-01 | Second Genome Inc | BICYCLOHETEROARYLFORBINDELSER AS P2X7 modulators and uses thereof |
| PE20091928A1 (es) * | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
| WO2010093706A2 (en) | 2009-02-10 | 2010-08-19 | The Scripps Research Institute | Chemically programmed vaccination |
| WO2010096722A1 (en) * | 2009-02-20 | 2010-08-26 | Takeda Pharmaceutical Company Limited | 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors |
| BRPI1011206A2 (pt) | 2009-05-25 | 2016-03-15 | Merck Patent Gmbh | administração contínua de ligantes de integrina para tratar câncer |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| KR20160147007A (ko) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체 |
| JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| ES2727379T3 (es) | 2014-12-03 | 2019-10-15 | Janssen Pharmaceutica Nv | Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5H)-ona y su uso como moduladores alostéricos negativos de receptores de mGlu2 |
| ES2727158T3 (es) | 2014-12-03 | 2019-10-14 | Janssen Pharmaceutica Nv | Ligandos para PET de mGluR2 radiomarcados |
| AU2016374571B2 (en) | 2015-12-18 | 2021-05-06 | Janssen Pharmaceutica Nv | Radiolabelled mGluR2/3 PET ligands |
| ES2820823T3 (es) | 2015-12-18 | 2021-04-22 | Janssen Pharmaceutica Nv | Ligandos PET mGluR2/3 radiomarcados |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2937779A1 (de) | 1979-09-19 | 1981-04-09 | Hoechst Ag, 6000 Frankfurt | Aminosaeurederivate und verfahren zu ihrer herstellung |
| DE3044236A1 (de) | 1980-11-25 | 1982-06-16 | Hoechst Ag, 6000 Frankfurt | Aminosaeurederivate und verfahren zu ihrer herstellung |
| ZA806976B (en) | 1979-11-13 | 1981-10-28 | Ventrex Lab Inc | Method and apparatus for carrying out solid phase in vitro diagnostic assays |
| FR2503155A2 (fr) | 1980-10-02 | 1982-10-08 | Science Union & Cie | Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
| FR2487829A2 (fr) | 1979-12-07 | 1982-02-05 | Science Union & Cie | Nouveaux imino acides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
| US4350704A (en) | 1980-10-06 | 1982-09-21 | Warner-Lambert Company | Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids |
| DE3177311D1 (de) | 1980-08-30 | 1994-06-09 | Hoechst Ag | Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung. |
| US4344949A (en) | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
| FR2492381A1 (fr) | 1980-10-21 | 1982-04-23 | Science Union & Cie | Nouveaux acides aza bicyclo alcane carboxyliques substitues leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
| DE19575012I2 (de) | 1980-10-23 | 2002-01-24 | Schering Corp | Carboxyalkyl-Dipeptide Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US4374847A (en) | 1980-10-27 | 1983-02-22 | Ciba-Geigy Corporation | 1-Carboxyalkanoylindoline-2-carboxylic acids |
| DE3226768A1 (de) | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
| GR78413B (ja) | 1981-12-29 | 1984-09-27 | Hoechst Ag | |
| DE3210496A1 (de) | 1982-03-23 | 1983-10-06 | Hoechst Ag | Neue derivate bicyclischer aminsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung |
| DE3211397A1 (de) | 1982-03-27 | 1983-11-10 | Hoechst Ag, 6230 Frankfurt | Spiro (4.(3+n))-2-aza-3-carbonsaeure-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| DE3211676A1 (de) | 1982-03-30 | 1983-10-06 | Hoechst Ag | Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung |
| DE3227055A1 (de) | 1982-07-20 | 1984-01-26 | Hoechst Ag, 6230 Frankfurt | Neue derivate der 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure als zwischenstufe und verfahren zu deren herstellung |
| DE3242151A1 (de) | 1982-11-13 | 1984-05-17 | Hoechst Ag, 6230 Frankfurt | Neue derivate tricyclischer aminosaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung, sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung |
| DE3246503A1 (de) | 1982-12-16 | 1984-06-20 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(5.3.0)-decan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
| DE3643012A1 (de) | 1986-12-17 | 1988-06-30 | Hoechst Ag | 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| DE3818850A1 (de) | 1988-06-03 | 1989-12-07 | Hoechst Ag | Oligopeptide mit zyklischen prolin-analogen aminosaeuren |
| PT100631B (pt) * | 1991-06-28 | 1999-06-30 | Smithkline Beecham Corp | Antagonistas biciclicos de fibrinogenio, seu uso e composicoes farmaceuticas que os contem |
| US5204350A (en) | 1991-08-09 | 1993-04-20 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives |
| US5217994A (en) | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
| DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| AU674553B2 (en) | 1992-10-14 | 1997-01-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| GB9225141D0 (en) * | 1992-12-01 | 1993-01-20 | Smithkline Beecham Corp | Chemical compounds |
| CA2150550A1 (en) | 1992-12-01 | 1994-06-09 | Melissa S. Egbertson | Fibrinogen receptor antagonists |
| SG63579A1 (en) * | 1992-12-21 | 1999-03-30 | Smithkline Beecham Corp | Bicyclic fibrinogen antagonists |
| HUT71796A (en) * | 1993-02-22 | 1996-02-28 | Merck & Co Inc | Condensed cyclic compounds with nitrogen heteroatoms and pharmaceutical compositions of fibrinogen receptor antagonistic activity containing them |
| CA2134192A1 (en) * | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
| US5563158A (en) * | 1993-12-28 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
| CA2190870A1 (en) * | 1994-05-27 | 1995-12-07 | George D. Hartman | Compounds for inhibiting osteoclast-mediated bone resorption |
| WO1996000730A1 (en) * | 1994-06-29 | 1996-01-11 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| EP0762882A4 (en) * | 1994-06-29 | 2002-09-11 | Smithkline Beecham Corp | Vibronectin Receptor Antagonists |
| WO1996026190A1 (en) * | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Integrin receptor antagonists |
| DE19516483A1 (de) * | 1995-05-05 | 1996-11-07 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| PT910563E (pt) * | 1995-06-29 | 2003-09-30 | Smithkline Beecham Corp | Antagonistas de receptores de integrina |
| KR19990076876A (ko) * | 1995-12-29 | 1999-10-25 | 스티븐 베네티아너 | 비트로넥틴 수용체 길항제 |
| CN1209063A (zh) * | 1995-12-29 | 1999-02-24 | 史密丝克莱恩比彻姆公司 | 玻连蛋白受体拮抗剂 |
| PL327694A1 (en) * | 1995-12-29 | 1998-12-21 | Smithkline Beecham Corp | Antagonists of vitronectin receptor |
| PT796855E (pt) * | 1996-03-20 | 2002-07-31 | Hoechst Ag | Inibicao da reabsorcao nos ossos e antagonistas de vitronectina |
| DE19629816A1 (de) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| DE19629817A1 (de) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
-
1996
- 1996-12-20 DE DE19653647A patent/DE19653647A1/de not_active Withdrawn
-
1997
- 1997-12-12 EP EP97121932.4A patent/EP0854140B1/de not_active Expired - Lifetime
- 1997-12-17 ZA ZA9711316A patent/ZA9711316B/xx unknown
- 1997-12-17 BR BR9706385A patent/BR9706385A/pt not_active IP Right Cessation
- 1997-12-18 AU AU48465/97A patent/AU730737B2/en not_active Ceased
- 1997-12-18 NZ NZ329430A patent/NZ329430A/xx unknown
- 1997-12-18 MX MX9710392A patent/MX9710392A/es unknown
- 1997-12-18 AR ARP970105995A patent/AR010370A1/es unknown
- 1997-12-18 IL IL12264197A patent/IL122641A0/xx unknown
- 1997-12-18 ID IDP973918A patent/ID19253A/id unknown
- 1997-12-18 CZ CZ974113A patent/CZ411397A3/cs unknown
- 1997-12-19 CN CN97129784A patent/CN1103775C/zh not_active Expired - Fee Related
- 1997-12-19 HU HU9702508A patent/HUP9702508A3/hu unknown
- 1997-12-19 NO NO19975976A patent/NO311644B1/no unknown
- 1997-12-19 RU RU97122265/04A patent/RU2198892C2/ru not_active IP Right Cessation
- 1997-12-19 CA CA002225273A patent/CA2225273A1/en not_active Abandoned
- 1997-12-20 PL PL97323970A patent/PL323970A1/xx unknown
- 1997-12-20 KR KR1019970073884A patent/KR19980064656A/ko not_active Application Discontinuation
- 1997-12-22 JP JP36552997A patent/JP4081167B2/ja not_active Expired - Lifetime
- 1997-12-22 US US08/995,521 patent/US6011045A/en not_active Expired - Lifetime
-
1998
- 1998-02-11 TW TW086119132A patent/TW523510B/zh active
-
1999
- 1999-10-05 US US09/412,331 patent/US6207663B1/en not_active Expired - Lifetime
-
2001
- 2001-02-06 US US09/777,011 patent/US6387895B1/en not_active Expired - Lifetime
-
2002
- 2002-05-13 US US10/142,975 patent/US6867208B2/en not_active Expired - Lifetime
-
2003
- 2003-01-22 CN CN03101487A patent/CN1440971A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US6867208B2 (en) | 2005-03-15 |
| EP0854140A3 (de) | 2000-03-08 |
| US20030027807A1 (en) | 2003-02-06 |
| NZ329430A (en) | 1999-05-28 |
| HUP9702508A2 (hu) | 1999-06-28 |
| HU9702508D0 (en) | 1998-03-02 |
| EP0854140B1 (de) | 2013-11-06 |
| ID19253A (id) | 1998-06-28 |
| CN1200374A (zh) | 1998-12-02 |
| PL323970A1 (en) | 1998-06-22 |
| CN1440971A (zh) | 2003-09-10 |
| US6387895B1 (en) | 2002-05-14 |
| AR010370A1 (es) | 2000-06-07 |
| JPH11147867A (ja) | 1999-06-02 |
| TW523510B (en) | 2003-03-11 |
| ZA9711316B (en) | 1998-06-22 |
| JP4081167B2 (ja) | 2008-04-23 |
| EP0854140A2 (de) | 1998-07-22 |
| AU4846597A (en) | 1998-06-25 |
| KR19980064656A (ko) | 1998-10-07 |
| MX9710392A (es) | 1998-06-30 |
| BR9706385A (pt) | 1999-07-20 |
| CZ411397A3 (cs) | 1998-07-15 |
| IL122641A0 (en) | 1998-08-16 |
| CA2225273A1 (en) | 1998-06-20 |
| AU730737B2 (en) | 2001-03-15 |
| NO975976L (no) | 1998-06-22 |
| RU2198892C2 (ru) | 2003-02-20 |
| NO975976D0 (no) | 1997-12-19 |
| US6011045A (en) | 2000-01-04 |
| HUP9702508A3 (en) | 2001-04-28 |
| US6207663B1 (en) | 2001-03-27 |
| DE19653647A1 (de) | 1998-06-25 |
| CN1103775C (zh) | 2003-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO311644B1 (no) | Vitronektinreseptor-antagonister, farmasöytisk preparat inneholdende disse og anvendelse derav | |
| EP0796855B1 (de) | Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten | |
| NO311719B1 (no) | Nye iminoderivater, en fremgangsmåte for deres fremstilling samt anvendelse av de samme | |
| NO311083B1 (no) | Nye cykloalkylderivater, fremgangsmåte for fremstilling derav, farmasöytiske preparater inneholdende forbindelsene samtanvendelse av forbindelsene | |
| US20090149526A1 (en) | Tetracyclic Indole Derivatives as Antiviral Agents | |
| SK9032000A3 (en) | Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists | |
| CZ2003616A3 (cs) | Bicyklické pyrrolylamidy jako inhibitory glykogenfosforylázy a farmaceutická kompozice, která je obsahuje | |
| EP0853084B1 (de) | Substituierte Purinderivate als Vitronectinrezeptor-Antagonisten | |
| CZ300127B6 (cs) | Zpusob prípravy meziproduktu inhibujících proteázy retroviru | |
| AU729760B2 (en) | Vitronectin receptor antagonists, their preparation and their use | |
| TW414795B (en) | A thiophene derivative and the pharmaceutical composition | |
| AU2001253538B2 (en) | Inhibitors of alpha l beta 2 mediated cell adhesion | |
| CZ294233B6 (cs) | Acylaminoalkenylenamidové deriváty, způsob jejich přípravy a farmaceutické prostředky, které je obsahují | |
| AU774382B2 (en) | Substituted purine derivatives as inhibitors of cell adhesion | |
| JP3913983B2 (ja) | ＴＮＦ−α阻害剤としての環式ヒドラジン誘導体 | |
| JP4550286B2 (ja) | 新規なアシルグアニジン誘導体、それらの製造方法、薬剤としてのそれらの使用及びそれらを含有する製薬組成物 | |
| US20040225111A1 (en) | Antagonist derivatives of the vitronectin receptor | |
| JP2003532732A5 (ja) | ||
| WO2001044237A1 (en) | Thienylalanine derivatives as inhibitors of cell adhesion | |
| US7259159B2 (en) | Guanidino derivatives as inhibitors of cell adhesion | |
| RU2195460C2 (ru) | Новые ингибиторы рассасывания костей и антагонисты рецептора витронектина |